Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644). Srinivasan, R., Bottaro, D. P., Choueiri, T. K., Vaishampayan, U. N., Rosenberg, J. E., Logan, T., Harzstark, A., Rini, B. I., Srinivas, S., Adams, L. M., Laubscher, K., Ottesen, L., McDermott, D. F., Linehan, W. AMER SOC CLINICAL ONCOLOGY. 2012
View details for DOI 10.1200/jco.2012.30.5_suppl.372
View details for Web of Science ID 000208892400371